Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by icecubeon Sep 29, 2015 5:11pm
56 Views
Post# 24146861

RE:RE:RE:RE:RE:RE:Caution

RE:RE:RE:RE:RE:RE:Caution"Could have happened"?

There is a huge difference between accusing a company and its officers of 'corporate malfeasance' and 'fraud' and saying that it 'could have happened'.

truthseeker2012 wrote: Hey it could have happened, when it was one o f the best run companies on the TSX. Now it has become one of the worst run companies on the TSX. 

If  I was running the show. it would have gone to $40. CPH could have bought lots of old drugs & raised the prices big time which is now common in the USA & made big easy money.

Only a stupid loser like you stupidess thinks Absoirca can't  become # 1 in the USA because they stalled at 20%. TEVA did not think like that with their drug & they passed 33% market share with an inferior product.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities